FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336025986> ?p ?o ?g. }

• W2336025986 endingPage "363" @default.
• W2336025986 startingPage "356" @default.
• W2336025986 abstract "Objectives: To evaluate the efficacy and safety of dapagliflozin 5 and 10 mg/d versus placebo in patients with type 2 diabetes and high baseline A1C defined as A1C ≥ 9% or ≥ 10%.Methods: A post-hoc analysis was conducted of pooled data from 9, 24-week, placebo-controlled clinical studies investigating dapagliflozin as monotherapy, add-on therapy to other oral antidiabetes drugs or insulin, or initial combination therapy with metformin.Results: At week 24, dapagliflozin 5 and 10 mg/d decreased A1C (≥ 9%: –1.37% and –1.39%, respectively, vs. –0.65% with placebo, both P < 0.0001 and ≥ 10%: –2.13% [P < 0.0001] and –1.59% [P = 0.0003], respectively, vs. –0.82% with placebo), reduced fasting plasma glucose as early as week 1 (P < 0.001 for each dose at all time points for both treatments), and decreased body weight (≥ 9%: P < 0.0001 vs. placebo for both doses; ≥ 10%: P = 0.0065 vs. placebo, 10 mg/d only). Among patients with baseline A1C ≥ 9% who received dapagliflozin 5 or 10 mg/d, 15.7% and 18.9%, respectively, achieved a ≥ 5% decrease in body weight (both P < 0.0001 vs. 3.6% with placebo). Dapagliflozin 10 mg/d decreased systolic and diastolic blood pressure (P < 0.0001 and P = 0.0074 vs. placebo). Adverse events were generally similar across treatment groups, with the exception of a greater frequency of genital infections and hypoglycemia (mostly minor episodes not requiring third-party assistance) in patients receiving dapagliflozin.Conclusion: In patients with poorly controlled type 2 diabetes defined as A1C ≥ 9% or ≥ 10%, dapagliflozin provided clinically meaningful improvements in glycemic parameters, body weight, and blood pressure, and was generally well tolerated, making it a good therapeutic option for patients with high A1C." @default.
• W2336025986 created "2016-06-24" @default.
• W2336025986 creator A5004454574 @default.
• W2336025986 creator A5063808837 @default.
• W2336025986 creator A5065626281 @default.
• W2336025986 creator A5076856427 @default.
• W2336025986 date "2016-04-18" @default.
• W2336025986 modified "2023-10-17" @default.
• W2336025986 title "Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C" @default.
• W2336025986 cites W1942610538 @default.
• W2336025986 cites W1953840628 @default.
• W2336025986 cites W1969335462 @default.
• W2336025986 cites W1973240292 @default.
• W2336025986 cites W1985015752 @default.
• W2336025986 cites W2001991301 @default.
• W2336025986 cites W2012117258 @default.
• W2336025986 cites W2019730753 @default.
• W2336025986 cites W2024566912 @default.
• W2336025986 cites W2033417941 @default.
• W2336025986 cites W2054361323 @default.
• W2336025986 cites W2055416829 @default.
• W2336025986 cites W2064097590 @default.
• W2336025986 cites W2068171948 @default.
• W2336025986 cites W2068561032 @default.
• W2336025986 cites W2076506641 @default.
• W2336025986 cites W2081510795 @default.
• W2336025986 cites W2082818798 @default.
• W2336025986 cites W2097168611 @default.
• W2336025986 cites W2100650274 @default.
• W2336025986 cites W2101329765 @default.
• W2336025986 cites W2101865653 @default.
• W2336025986 cites W2103417556 @default.
• W2336025986 cites W2110664743 @default.
• W2336025986 cites W2114031829 @default.
• W2336025986 cites W2114276479 @default.
• W2336025986 cites W2117505171 @default.
• W2336025986 cites W2120922908 @default.
• W2336025986 cites W2122077393 @default.
• W2336025986 cites W2123946565 @default.
• W2336025986 cites W2123984464 @default.
• W2336025986 cites W2124826696 @default.
• W2336025986 cites W2128050336 @default.
• W2336025986 cites W2132467967 @default.
• W2336025986 cites W2141713511 @default.
• W2336025986 cites W2153399820 @default.
• W2336025986 cites W2153839551 @default.
• W2336025986 cites W2161852973 @default.
• W2336025986 cites W2162449758 @default.
• W2336025986 cites W2163229244 @default.
• W2336025986 cites W2164518074 @default.
• W2336025986 cites W2172124430 @default.
• W2336025986 cites W2337454357 @default.
• W2336025986 cites W2418467016 @default.
• W2336025986 cites W935688119 @default.
• W2336025986 doi "https://doi.org/10.1080/00325481.2016.1173514" @default.
• W2336025986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27043045" @default.
• W2336025986 hasPublicationYear "2016" @default.
• W2336025986 type Work @default.
• W2336025986 sameAs 2336025986 @default.
• W2336025986 citedByCount "7" @default.
• W2336025986 countsByYear W23360259862017 @default.
• W2336025986 countsByYear W23360259862019 @default.
• W2336025986 crossrefType "journal-article" @default.
• W2336025986 hasAuthorship W2336025986A5004454574 @default.
• W2336025986 hasAuthorship W2336025986A5063808837 @default.
• W2336025986 hasAuthorship W2336025986A5065626281 @default.
• W2336025986 hasAuthorship W2336025986A5076856427 @default.
• W2336025986 hasConcept C126322002 @default.
• W2336025986 hasConcept C126894567 @default.
• W2336025986 hasConcept C134018914 @default.
• W2336025986 hasConcept C142724271 @default.
• W2336025986 hasConcept C197934379 @default.
• W2336025986 hasConcept C204787440 @default.
• W2336025986 hasConcept C27081682 @default.
• W2336025986 hasConcept C2777180221 @default.
• W2336025986 hasConcept C2777422806 @default.
• W2336025986 hasConcept C2779306644 @default.
• W2336025986 hasConcept C2780323712 @default.
• W2336025986 hasConcept C2780668416 @default.
• W2336025986 hasConcept C555293320 @default.
• W2336025986 hasConcept C71924100 @default.
• W2336025986 hasConcept C90924648 @default.
• W2336025986 hasConceptScore W2336025986C126322002 @default.
• W2336025986 hasConceptScore W2336025986C126894567 @default.
• W2336025986 hasConceptScore W2336025986C134018914 @default.
• W2336025986 hasConceptScore W2336025986C142724271 @default.
• W2336025986 hasConceptScore W2336025986C197934379 @default.
• W2336025986 hasConceptScore W2336025986C204787440 @default.
• W2336025986 hasConceptScore W2336025986C27081682 @default.
• W2336025986 hasConceptScore W2336025986C2777180221 @default.
• W2336025986 hasConceptScore W2336025986C2777422806 @default.
• W2336025986 hasConceptScore W2336025986C2779306644 @default.
• W2336025986 hasConceptScore W2336025986C2780323712 @default.
• W2336025986 hasConceptScore W2336025986C2780668416 @default.
• W2336025986 hasConceptScore W2336025986C555293320 @default.
• W2336025986 hasConceptScore W2336025986C71924100 @default.
• W2336025986 hasConceptScore W2336025986C90924648 @default.
• W2336025986 hasIssue "4" @default.

• next